The CSL Limited (ASX: CSL) share price has been a very strong performer on Wednesday.
In afternoon trade, the biotherapeutics giant’s shares are up a sizeable 8% to $262.20.
Why is the CSL share price charging higher?
Investors have been bidding the CSL share price higher today following the release of its half year results.
For the six months ended 31 December, CSL reported a 4% increase in constant currency revenue to US$5,993 million. This comprises a 2% decline in CSL Behring revenue to US$4,216 million and an 18% lift in Seqirus revenue to US$1,592 million.
However, due to margin weakness caused largely by plasma collection headwinds, CSL posted a 5% constant currency decline in net profit after tax to US$1,722 million.
So why are its shares rising?
A couple of items appear to have given the CSL share price a boost today. The first is positive commentary regarding the outlook for plasma collections.
CSL’s CEO, Paul Perreault, commented: “Our core franchise, the immunoglobulin portfolio, has been impacted by the industrywide constraints on collecting plasma in FY21 during the course of the global pandemic. We have responded by implementing multiple initiatives in our plasma collections network, which has given rise to significant improvement in plasma volumes collected. Given the long-term nature of our manufacturing cycle, this will underpin stronger Ig and albumin sales going forward.”
What else?
Also giving the CSL share price a lift was its guidance for FY 2022.
Although the company has reaffirmed its guidance for a net profit after tax in the range of US$2.15 billion to US$2.25 billion at constant currency, this guidance now includes US$90 million to US$110 million in transaction costs related to the Vifor Pharma acquisition. Whereas its prior guidance did not include these costs.
The response
Goldman Sachs has responded to the company’s results.
It commented: “Solid headline beats and effective +4-5% guidance upgrade despite mixed franchise performance.”
Goldman doesn’t currently have a rating on the CSL share price. This is due to it assisting with the aforementioned Vifor Pharma acquisition.
The post CSL (ASX:CSL) share price jumps 8% on guidance upgrade and positive plasma outlook appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- Why CSL, Liontown, Nearmap, and Treasury Wine shares are storming higher
- ASX 200 (ASX:XJO) midday update: CSL upgrades guidance, Treasury Wine jumps
- CSL (ASX:CSL) delivers US$1.7bn half year profit and tips plasma collection rebound
- Down by a quarter in less than three months, is the CSL (ASX:CSL) share price a buy?
- 5 things to watch on the ASX 200 on Wednesday
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/wZT2aSB
Leave a Reply